Neoadjuvant PD-1 blockade in resectable lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • B7-H1 Antigen
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

abstract

  • Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).

authors

publication date

  • May 24, 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1716078

PubMed ID

  • 29658848

Additional Document Info

start page

  • 1976

end page

  • 1986

volume

  • 378

number

  • 21